Related Experiment Videos
Rasmus Søgaard Hansen1, Julie Brogaard Larsen2,3, Pernille Just Vinholt1,4
1Blodprøver og Biokemi, Odense Universitetshospital.
Insights
Antiphospholipid syndrome (APS) involves antibodies against phospholipid-binding proteins, increasing risks of blood clots and pregnancy issues. This review covers the 2023 classification criteria and management of APS.
Area of Science:
- Immunology
- Rheumatology
- Hematology
Background:
- Antiphospholipid syndrome (APS) is characterized by antiphospholipid antibodies (aPL) targeting phospholipid-binding proteins.
- APS significantly elevates the risk of thromboembolism and obstetric complications.
- Understanding APS is crucial for managing associated health risks.
Approach:
- This review summarizes the 2023 international classification criteria for APS.
- It details the six clinical and two laboratory domains essential for diagnosis.
- The review outlines current specialist approaches to APS diagnosis and treatment.
Key Points:
- The 2023 criteria encompass venous, arterial, and microvascular events, obstetric issues, cardiac valve disease, and thrombocytopenia.
- Laboratory confirmation requires lupus anticoagulant, anti-cardiolipin, or anti-β2-glycoprotein-I antibodies.
- Accurate diagnosis relies on integrating clinical and laboratory findings.
Conclusions:
- APS diagnosis and management require specialized medical expertise.
- This review provides a comprehensive overview for clinicians.
- Adherence to updated criteria ensures optimal patient care for APS.
Abstract:
Individuals with antiphospholipid syndrome (APS) have antibodies directed against phospholipid-binding proteins (aPL). The condition is most associated with an increased risk of thromboembolism and obstetric complications. The 2023 classification criteria for APS include six clinical domains (venous thromboembolism, arterial thrombosis, microvascular events, obstetric events, cardiac valve, thrombocytopaenia) and two laboratory domains (lupus anticoagulant, and anti-cardiolipin or anti-β2-glycoprotein-I antibodies). Diagnosis and treatment of APS are specialist tasks and are summarised in this review.